Island Pharmaceuticals (ASX:ILA) has secured over AU$1 million through the exercise of 14.4 million options at AU$0.07 each by existing and substantial shareholders, according to a Wednesday Australian bourse filing.
The funds will be used to drive regulatory initiatives under the US Food and Drug Administration animal rule pathway and support US government engagement to position Galidesivir for inclusion in national stockpiles as a key antiviral countermeasure, the filing added.
The company's shares fell 2% in recent Wednesday trade.